GlassScriptPhysician profile
Anna Austin
NPI 1679085435
$5,622.38
in general payments reported to CMS, 2019-2025
33 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,073 · 2022: $1,012 · 2023: $940 · 2024: $1,366 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,526 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.34 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $865.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $542.76 | 2021-2025 | |
| Pfizer INC. | $360.01 | 2021-2025 | |
| Lundbeck LLC | $338.98 | 2021-2025 | Vyepti, Rexulti |
| Amgen INC. | $303.16 | 2021-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $294.62 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $262.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $254.69 | 2024-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $222.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $211.35 | 2021-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $211.06 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.33 | 2021-2025 | Jardiance |
| Biogen, INC. | $174.98 | 2021-2025 | Leqembi |
| Novo Nordisk INC | $158.13 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $152.74 | 2022-2025 | Verquvo, Capvaxive, Gardasil |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $149.45 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $127.31 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $117.00 | 2021-2025 | Nexletol |
| Abbott Laboratories | $110.54 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $98.81 | 2021-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $75.97 | 2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.89 | 2021 | |
| Idorsia Pharmaceuticals US INC | $69.54 | 2022-2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $36.62 | 2025 | |
| Phathom Pharmaceuticals, INC. | $36.02 | 2024-2025 | Voquezna |
| Dexcom, INC. | $33.31 | 2024-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $30.66 | 2024 | Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $27.52 | 2021 | |
| Adamas Pharmaceuticals, INC. | $20.56 | 2021 | |
| Corium, LLC | $19.30 | 2023 | Adlarity |
| Bausch Health US, LLC | $17.91 | 2023 | Aplenzin |
| Sanofi-Aventis U.S. LLC | $11.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.